Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Acquisitions & Divestments (2024)

Harvard Bioscience (HBIO) has disclosed Change in Acquisitions & Divestments for 1 consecutive years, with $1.4 million as the latest value for Q2 2024.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $1.4 million in Q2 2024 year-over-year; TTM through Mar 2025 was $1.4 million, a 187.68% increase, with the full-year FY2024 number at $1.9 million, changed N/A from a year prior.
  • Change in Acquisitions & Divestments was $1.4 million for Q2 2024 at Harvard Bioscience, up from $495000.0 in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $1.4 million in Q2 2024 to a low of $495000.0 in Q1 2024.